Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - ignatia (ph.eur.hom.) d10, moschus d200 - omeopatici gocce - strychnos i (ph. eur.hom.) d4, strychnos i (ph. eur.hom.) d10, strychnos i (ph. eur.hom.) d30, strychnos i (ph. eur.hom.) d200, muschio d6, muschio d30, muschio d200 ana parti 5 µl, excipiens ad una soluzione per 1 ml, corrisp. ethanolum 35 % v/v. - in caso di isteriche erregungszuständen - farmaci omeopatici

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mieloma multiplo - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combinazione con bortezomib, talidomide e desametasone per il trattamento di pazienti adulti con nuova diagnosi di mieloma multiplo che sono eleggibili per il trapianto di cellule staminali autologhe. in combinazione con lenalidomide e desametasone, o bortezomib e desametasone per il trattamento di pazienti adulti con mieloma multiplo che hanno ricevuto almeno una precedente terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. come monoterapia per il trattamento di pazienti adulti con recidivo e refrattario mieloma multiplo, la cui prima terapia incluso un inibitore del proteasoma e un agente immunomodulante e che hanno dimostrato la progressione della malattia, l'ultima terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Unione Europea - italiano - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Unione Europea - italiano - EMA (European Medicines Agency)

takeda pharma a/s - citrato di ixazomib - mieloma multiplo - agenti antineoplastici - ninlaro in combinazione con lenalidomide e desametasone è indicato per il trattamento di pazienti adulti con mieloma multiplo che hanno ricevuto almeno una terapia precedente.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - mieloma multiplo - immunosoppressori - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide accordo, in combinazione con desametasone, è indicato per il trattamento del mieloma multiplo in pazienti adulti che hanno ricevuto almeno una precedente terapia. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Unione Europea - italiano - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mieloma multiplo - agenti antineoplastici - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - mieloma multiplo - agenti antineoplastici - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomide - mieloma multiplo - immunosoppressori - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Unione Europea - italiano - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma multiplo - agenti antineoplastici - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.